Pabón V, Dumortier J, Gincul R, Baulieux J, Ducerf C, Trépo C, Souquet J-C, Zoulim F, Paliard P, Boillot O, Bost M, Lachaux A
Centre de Référence Maladies Rares-Maladie de Wilson, Hospices Civils de Lyon, Lyon, France.
Gastroenterol Clin Biol. 2008 Apr;32(4):378-81. doi: 10.1016/j.gcb.2008.01.033. Epub 2008 Apr 10.
Wilson's disease is a hereditary defect in hepatic copper metabolism, causing hepatic, neurological and/or psychiatric manifestations. For patients with severe disease, liver transplantation is the treatment of choice. The aim of this study was to report the long-term outcome of patients who underwent liver transplantation for Wilson's disease.
Thirteen patients with Wilson's disease, transplanted in Lyon France between January 1987 and May 2006, were including in this study: eight women and five men, aged eight to 53 years (median 20 years, seven children and six adults). The diagnosis of Wilson's disease was established before liver transplantation.
The indication for liver transplantation was chronic (69%) or fulminant liver failure (31%). The median follow-up after liver transplantation was 10 years with 100% patient survival. Copper metabolism returned to normal in all patients. None of the patients with exclusive liver disease required chelation treatment after liver transplantation and none developed neurological symptoms of Wilson's disease.
Liver transplantation totally reverses the abnormalities of copper metabolism and subsequent hepatic failure, but the course of neurological symptoms remains unpredictable. Long-term patient survival can be excellent without occurrence of neurological complications.
威尔逊病是一种遗传性肝铜代谢缺陷病,可导致肝脏、神经和/或精神方面的表现。对于重症患者,肝移植是首选治疗方法。本研究的目的是报告接受威尔逊病肝移植患者的长期预后情况。
本研究纳入了1987年1月至2006年5月在法国里昂接受移植的13例威尔逊病患者:8名女性和5名男性,年龄8至53岁(中位数20岁,7名儿童和6名成人)。威尔逊病的诊断在肝移植前确立。
肝移植的指征为慢性(69%)或暴发性肝衰竭(31%)。肝移植后的中位随访时间为10年,患者生存率为100%。所有患者的铜代谢均恢复正常。所有单纯肝脏疾病患者在肝移植后均无需螯合治疗,且无一例出现威尔逊病的神经症状。
肝移植可完全逆转铜代谢异常及随后的肝衰竭,但神经症状的病程仍不可预测。患者长期生存率可良好,且无神经并发症发生。